secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001404644-25-000098
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome
--------------------------------------------------------------------------------

- All 8 pediatric participants (ages 4-10) showed functional gains across spectrum of disease severity.
- 35 developmental milestones/skills acquired across hand function, language/communication, and gross motor domains.
- NGN-401 at the 1E15 vg dose was generally well-tolerated with no evidence of HLH in any participant.
- Gains were durable with continued skill acquisition observed up to 24 months post treatment.
- Company to discuss results at Stifel 2025 Healthcare Conference webcast on November 12, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000098/0001404644-25-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000098/ngne-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer